La hipermocisteinemia un factor de riesgo de enfermedad cardiovascular, fácil de modificar

Abstract

The homicysteine (hcy), is an intermedia metabolity in the transformation of metionine to cysteine. Metabolic elimination of these substance depends on vitamins B6, B12 and folic acid and enzymes such like cistationine Â-sintase, and metilentetrahidrofolate reductase. The common denominators in heredity deficiency of one fo these enzymes or the ones taking part of the metabolism of the folate or the vitamin B12 are a significant raise of Hcy in blood and cardiovascular diseases. Since these observations, they began to relate the Hcy vith vascular disease. Researches in the last two decades point a moderate raise of Hcy as a risk factor in vascular alterations. This metabolity for mechanisms including activation of some ciagulation factors and inactivation of natural anticoagulants helps the thrombi forming and vascular endothelium damage. The raise of this substance is easy to midify through drug and diet media. Due to this, the Hcy takes part of an analytic parameter of growing use in clinical practice, in cardiovascular diseases patients, in the diagnosis and motitorizing of the response to anemia treatment caused by lack of vitamins B12 and/or folic acid, the value of the risk of having defects of the neural tube or espontaneus abortion, specially in cases where they are repetitive.